Download PDF
Thromb Haemost 1996; 76(04): 603-609
DOI: 10.1055/s-0038-1650629
Original Article
Schattauer GmbH Stuttgart

Human Umbilical Vein Smooth Muscle Cells as a Model to Study Thrombin Generation and Function: Effect of Thrombin Inhibitors

Rose-Marie Catalioto
The Department of Pharmacology, Menarini Ricerche Spa, Laboratori di Pisa, Pisa, Italy
,
Paola Cucchi
The Department of Pharmacology, Menarini Ricerche Spa, Laboratori di Pisa, Pisa, Italy
,
Anna Rita Renzetti
The Department of Pharmacology, Menarini Ricerche Spa, Laboratori di Pisa, Pisa, Italy
,
Marco Criscuoli
The Department of Pharmacology, Menarini Ricerche Spa, Laboratori di Pisa, Pisa, Italy
,
Alessandro Subissi
The Department of Pharmacology, Menarini Ricerche Spa, Laboratori di Pisa, Pisa, Italy
› Author Affiliations
Further Information

Publication History

Received 19 December 1995

Accepted after resubmission 04 June 1996

Publication Date:
10 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The aim of the present work was to study how human umbilical vein smooth muscle cells (HUVSMC) can initiate the coagulation process and to investigate the responses of these cells to thrombin. Exposure of HUVSMC to recalcified human plasma led to a time-dependent production of thrombin, measured both as amidolytic activity and as release of fibrinopeptide A. Thrombin activity was dose-dependently reduced by an anti-human tissue factor antibody (76 ± 3% at 10 Μg/ml) and by inhibitors like heparin, rec-hirudin, hirulog-1, Napap and hiru-norm, a novel hirudin-like thrombin inhibitor (IC50 = 2 ± 0.4, 8 ± 1, 130 ± 22, 199 ± 29 and 68 ± 8nM, respectively). The release of fibrinopeptide A was similarly prevented (IC50 = 14 ± 1,132 ± 25 and 50 ± 8 nM for rec-hirudin, Napap and hirunorm, respectively). Exogenously added thrombin increased thymidine incorporation into HUVSMC to 240 ± 30% of basal (EC50 = 0.49 ± 0.09 nM) and thrombin inhibitors blocked this effect (IC50 = 10 ± 3, 37 ± 17, 343 ± 165 and 1402 ± 758 nM for rec-hirudin, hirunorm, Napap and hirulog-1, respectively). Also recalcified human plasma was mitogenic for HUVSMC and its effect was mainly due to endogenously generated thrombin, as shown by the use of thrombin inhibitors. In conclusion, HUVSMC are capable of initiating the extrinsic coagulation cascade, leading to the formation of thrombin which promotes clotting and stimulates DNA synthesis. Thrombin inhibitors prevent both coagula-tive and cellular effects of thrombin.

 

  • References

  • 1 Davi EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995; 74: 1-6
    PubMedGoogle Scholar
  • 2 Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66: 67-79
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Ruf W, Edgington TS. Structural biology of tissue factor, the initiator of thrombogenesis in vivo. FASEB 1994; 8: 385-390
    CrossrefPubMedGoogle Scholar
  • 4 Taubman MB, Marmur JD, Rosenfield CL, Guha A, Nichtberger S, Nemerson Y. Agonist-mediated tissue factor expression in cultured vascular smooth muscle cells. J Clin Invest 1993; 91: 547-552
    CrossrefPubMedGoogle Scholar
  • 5 Parolari A, Antona C, Colli S, Mussoni L. Serum and thrombin induce tissue factor expression in human smooth muscle cells. Thromb Haemost 1995; 73: 1182
    PubMedGoogle Scholar
  • 6 Ogletree ML, Natarajan S, Seiler SM. Thrombin receptors as drug discovery targets. Perspectives in Drug Discovery and Design 1993; 1: 527-536
    PubMedGoogle Scholar
  • 7 De Caterina R, Sicari R. Cellular effects of thrombin: pharmacology of the receptor(s) in various cell types and possible development of receptor antagonists. Pharmacol Res 1993; 27: 1-19
    PubMedGoogle Scholar
  • 8 Coughlin SR, Vu TKH, Hung DT, Wheaton VI. Characterization of a functional thrombin receptor, issues and opportunities. J Clin Invest 1992; 89: 351-355
    CrossrefPubMedGoogle Scholar
  • 9 Fager G. Thrombin and proliferation of vascular smooth muscle cells. Circ Res 1995; 77: 645-650
    CrossrefPubMedGoogle Scholar
  • 10 Tesfamariam B. Distinct receptors and signalling pathways in a-thrombin and thrombin receptor peptide-induced vascular contractions. Circ Res 1994; 74: 930-936
    CrossrefPubMedGoogle Scholar
  • 11 Baron A, Loirand G, Pacaud P, Mironneau C, Mironneau J. Dual effect of thrombin on voltage-dependent Ca2+ channels of portal vein smooth muscle cells. Circ Res 1993; 72: 1317-1325
    CrossrefPubMedGoogle Scholar
  • 12 Wojta J, Gallichio M, Zoellner H, Hufnagl P, Last K, Filonzi EL, Binder BR, Hamilton JA, Mcgrath K. Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells. Thromb Haemost 1993; 70: 469-474
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Vu TKH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-1068
    CrossrefPubMedGoogle Scholar
  • 14 Zhong C, Hayzer DJ, Corson MA, Runge MS. Molecular cloning of the rat vascular smooth muscle thrombin receptor. J Biol Chem 1992; 267: 16975-16979
    PubMedGoogle Scholar
  • 15 Rasmussen UB, Vouret-Craviari V, Jallat S, Schlessinger Y, Pages G, Pavirani A, Lecocq JP, Pouyssegur J, Obberghen-Schilling E. cDNA cloning and expression of a hamster a-thrombin receptor coupled to Ca2+ mobilization. FEBS Lett 1991; 288: 123-128
    CrossrefPubMedGoogle Scholar
  • 16 Grand RJA, Tumell AS, Grabham PW. Cellular consequences of thrombin-receptor activation. Biochem J 1996; 313: 353-368
    CrossrefPubMedGoogle Scholar
  • 17 McNamara CA, Sarembock IJ, Gimple LW, Fenton IIJW, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 1993; 91: 94-98
    CrossrefPubMedGoogle Scholar
  • 18 Hung DT, Vu TK, Nelken NA, Coughlin SR. Thrombin-induced events in non-platelet cells are mediated by the unique proteolytic mechanism established for the cloned platelet thrombin receptor. J Cell Biol 1992; 116: 827-832
    CrossrefPubMedGoogle Scholar
  • 19 Hung DT, Vu TK, Wheaton VI, Ishii K, Coughlin SR. Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation. J Clin Invest 1992; 89: 1350-1353
    CrossrefPubMedGoogle Scholar
  • 20 Joseph S, MacDermot J. The N-terminal thrombin receptor fragment SFLLRN, but not catalytically inactive thrombin-derived agonists, activate U937 human monocytic cells: evidence for receptor hydrolysis in thrombin-dependent signalling. Biochem J 1993; 290: 571-577
    CrossrefPubMedGoogle Scholar
  • 21 Stiernberg J, Redin WR, Warner WS, Carney DH. The role of thrombin and thrombin receptor activating peptide (TRAP-508) in initiation of tissue repair. Thromb Haemost 1993; 70: 158-162
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Jenkins AL, Howells GL, Scott E, Lebonniec BF, Curtis MA, Stone SR. The response to thrombin of human neutrophiles: Evidence for two novel receptors. J Cell Sci 1995; 108: 3059-3066
    CrossrefPubMedGoogle Scholar
  • 23 Kaiser B, Hauptmann J. Pharmacology of synthetic thrombin inhibitors of the tripeptide type. Cardiovasc Drug Rev 1992; 10: 71-87
    CrossrefPubMedGoogle Scholar
  • 24 Tapparelli C, Mettemich R, Ehrhardt C, Cook NS. Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. TIPS 1993; 14: 366-376
    PubMedGoogle Scholar
  • 25 Deutsch E, Rao AK, Colman RW. Selective thrombin inhibitors: the next generation of anticoagulants. J Am Coll Cardiol 1993; 22: 1089-1092
    CrossrefPubMedGoogle Scholar
  • 26 Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90: 1522-1536
    CrossrefPubMedGoogle Scholar
  • 27 Chiu AT, Mousa SA, Pease LJ, Roscoe WA, Bozarth JM, Reilly TM, Smith RD, Timmermans PBMWM. Inhibition of the thrombin-platelet reactions by Dup754. Biochem Biophys Res Commun 1991; 179: 1500-1508
    CrossrefPubMedGoogle Scholar
  • 28 Bacher P, Walenga JM, Iqbal O, Bajusz S, Breddin K, Fareed F. The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models. Thromb Res 1993; 71: 251-263
    CrossrefPubMedGoogle Scholar
  • 29 Kirchhofer D, Tschopp TB, Hadvary P, Baumgartner HR. Endothelial cells stimulated with tumor necrosis factor-a express varying amounts of tissue factor resulting in inhomogeneous fibrin deposition in a native blood flow system, effects of thrombin inhibitors. J Clin Invest 1994; 93: 2073-2083
    CrossrefPubMedGoogle Scholar
  • 30 Herbert JM, Lamarche I, Dol F. Induction of vascular smooth muscle cell growth by selective activation of the thrombin receptor. FEBS Lett 1992; 301: 155-158
    CrossrefPubMedGoogle Scholar
  • 31 Hedin U, Frebelius S, Snachez J, Dryjski M, Swedenborg J. Antithrombin III inhibits thrombin-induced proliferation in human arterial smooth muscle cells Arterioscler. Thromb 1994; 14: 254-260
    PubMedGoogle Scholar
  • 32 Lombardi A, Nastri F, Galdiero S, Della Morte R, Stiano N, Pedone C, Pavone V. Rational design of enzymatically resistant, peptide based, multi-site directed, a-thrombin inhibitors. American Peptide Symposium, Columbus (Ohio, USA), June 18-23 1995 abstract n° P930
    PubMedGoogle Scholar
  • 33 Chamley-Champbell J, Campbell GR, Ross R. The smooth muscle cell in culture. Physiol Rev 1979; 59: 1-61
    CrossrefPubMedGoogle Scholar
  • 34 Jaffe EA. Culture of human endothelial cells. Transplant Proc 1980; 12: 49-53
    PubMedGoogle Scholar
  • 35 Owens GK, Loeb A, Gordon D, Thompson M. Expression of smooth muscle cell-specific a isoactin in cultured vascular smooth muscle cells: relationship between growth and cytodifferentiation. J Cell Biol 1986; 102: 343-352
    CrossrefPubMedGoogle Scholar
  • 36 Crutchley DJ, Conanan LB, Toledo AW, Solomon DE, Que BG. Effects of prostacyclin analogues on human endothelial cell tissue factor expression. Arterioscler Thrombosis 1993; 13: 1082-1089
    PubMedGoogle Scholar
  • 37 Mulder AB, Blom NR, Smit JW, Ruiters MH, van der Meer J, Halie MR, Bom VJJ. Basal tissue factor expression in endothelial cell cultures is caused by contaminating smooth muscle cells. Reduction by using chymo-trypsin instead of collagenase. Thromb Res 1995; 80: 399-411
    CrossrefPubMedGoogle Scholar
  • 38 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implication for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134: 1087-1097
    PubMedGoogle Scholar
  • 39 Brinkman HJM, Mertens K, Holthuis J, Zwart-Huinink LA, Grijm K, van Mourik JA. The activation of human blood coagulation factor X on the surface of endothelial cells: a comparison with various vascular cells, platelets and monocytes. Brit J haemat 1994; 87: 332-342
    CrossrefPubMedGoogle Scholar
  • 40 Kanthou C, Dennehy U, Benzakour O, Kakkar V. Conversion of prothrombin to an enzymatically and mitogenically active form at the surface of human vascular smooth muscle cells. Thromb Haemost 1995; 73: 911
    PubMedGoogle Scholar
  • 41 Sekiya F, Usui H, Inoue K, Fukudome K, Morita T. Activation of prothrombin by a novel membrane-associated protease. J Biol Chem 1994; 269: 32441-32445
    PubMedGoogle Scholar
  • 42 Nystedt S, Emilsson K, Wahlestedt C, Sundelin J. Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci 1994; 91: 9208-9212
    CrossrefPubMedGoogle Scholar
  • 43 Nystedt S, Emilsson K, Larsson AK, Strombeck B, Sundelin J. Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. Eur J Biochem 1995; 232: 84-89
    CrossrefPubMedGoogle Scholar
  • 44 Santulli RJ, Derian CK, Darrow AL, Tomko KA, Eckardt AJ, Seiberg M, Scarborough RM, Andrade Gordon P. Evidence for the presence of a protease-activated receptor distinct from the thrombin receptor in human keratinocytes. Proc Natl Acad Sci 1995; 92: 9151-9155
    CrossrefPubMedGoogle Scholar
  • 45 Vouret-Craviari V, Van Obberghen-Schilling E, Rasmussen UB, Pavirani A, Lecocq JP, Poyssegur J. Synthetic a-thrombin receptor peptides activate G protein-coupled signaling pathways but are unable to induce mitogenesis. Mol Biol of the Cell 1992; 3: 95-102
    PubMedGoogle Scholar
  • 46 Vouret-Craviari V, Van Obberghen-Schilling E, Scimeca JC, Van Obberghen E, Pouyssegur J. Differential activation of p44maPk (ERK1) by a-thrombin and thrombin receptor peptide agonist. Biochem J 1993; 289: 14
    PubMedGoogle Scholar
  • 47 Lau LF, Pumiglia K, Cote YP, Feinstein MB. Thrombin receptor agonist peptides, in contrast to thrombin itself are not full agonists for activation and signal transduction in human platelets in the absence of platelet-derived secondary mediators. Biochem J 1994; 303: 391-401
    CrossrefPubMedGoogle Scholar
  • 48 Connely TM, Condra C, Feng DM, Cook JJ, Stranieri MT, Reilly CF, Nutt RF, Gould RJ. Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides. Thromb Haemost 1994; 72: 627-633
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Kanthou C, Benzakour O, Patel G, Deasman J, Kakkar VV, Lupu F. Thrombin receptor activating peptide (TRAP) stimulates mitogenesis, c-fos and PDGF-A gene expression in human vascular smooth muscle cells. Thromb Haemost 1995; 74: 1340-1347
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Kanthou C, Parry G, Eijelath E, Kakkar VV, Demoliou-Mason C. Thrombin-induced proliferation and expression of platelet-derived growth factor-A chain gene in human vascular smooth muscle cells. FEBS Lett 1992; 314: 143-148
    CrossrefPubMedGoogle Scholar
  • 51 Witting JI, Bourdon P, Brezniak DV, Maraganore JM, Fenton JW. Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biochem J 1992; 283: 737-743
    CrossrefPubMedGoogle Scholar
  • 52 Newby AC, George SJ. Proposed roles for growth factors in mediating smooth muscle proliferation in vascular pathologies. Cardiovasc Res 1993; 27: 1173-1183
    CrossrefPubMedGoogle Scholar
  • 53 Benzakour O, Formstone C, Rahman S, Kanthou C, Dennehy U, Scully MF, Cooper DN, Kakkar VV. Evidence for protein S receptor(s) on human vascular smooth muscle cells. Analysis of the binding characteristics and mitogenic properties of protein S on human vascular smooth muscle cells. Thromb Haemost 1995; 73: 939
    PubMedGoogle Scholar
  • 54 Harker LA, Hanson SR, Runge MS. Thrombin hypothesis of thrombus generation and vascular lesion formation. Am J Physiol 1995; 75: 12B-15B
    PubMedGoogle Scholar
  • 55 Schwartz SM, Reidy MA, O’Brien ERM. Assessment of factors important in atherosclerotic occlusion and restenosis. Thromb Haemost 1995; 74: 541-551
    Article in Thieme ConnectPubMedGoogle Scholar
  • 56 Osterud B, Bajaj MS, Bajaj SP. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. Thromb Haemost 1995; 73: 873-875
    Article in Thieme ConnectPubMedGoogle Scholar
  • 57 Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel and in the atherosclerotic plaque. Proc Natl Acad Sci 1989; 86: 2839-2843
    CrossrefPubMedGoogle Scholar
  • 58 Drake TA, Morrissey JH, Edgington TS. Immunohistochemical detection of tissue factor in human atherosclerotic plaques. Circ 1989; 80: 11-182
    PubMedGoogle Scholar
  • 59 Weiss HJ, Turitto VT, Baumgartner HR, Nemerson Y, Hoffman T. Evidence for the presence of tissue factor activity on the subendothelium. Blood 1989; 73: 968-975
    PubMedGoogle Scholar
  • 60 Speidel CM, Edgington TS, Eisenberg PR, Ab endshein DR. Tissue factor induces prolonged procoagulant activity on the luminal surface of rabbit aortas after balloon-induced injury. Circ 1994; 90: 1-344
    CrossrefPubMedGoogle Scholar
  • 61 Nelken NA, Soifer SJ, O’Keefe J, Vu TKH, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 1992; 90: 1614-1621
    CrossrefPubMedGoogle Scholar
  • 62 Fischer EG, Wolfram R, Mueller BM. Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Res 1995; 55: 1629-1632
    PubMedGoogle Scholar